The master neural transcription factor BRN2 is an androgen receptor–suppressed driver of neuroendocrine differentiation in prostate cancer

Cancer Discovery

Volumn 7, Issue 1, 2017, Pages 54-71

  Bishop, Jennifer L ^a   Thaper, Daksh ^a,b   Vahid, Sepideh ^a,b   Davies, Alastair ^a   Ketola, Kirsi ^a   Kuruma, Hidetoshi ^a   Jama, Randy ^a   Nip, Ka Mun ^a,b   Angeles, Arkhjamil ^a   Johnson, Fraser ^a   Wyatt, Alexander W ^a,b   Fazli, Ladan ^a,b   Gleave, Martin E ^a,b   Lin, Dong ^a   Rubin, Mark A ^c   Collins, Colin C ^a,b   Wang, Yuzhuo ^a,b   Beltran, Himisha ^c   Zoubeidi, Amina ^a,b  

^a VANCOUVER PROSTATE CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BRN2; ENZALUTAMIDE; NERVE CELL ADHESION MOLECULE L1; SMALL INTERFERING RNA; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; AR PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; PHENYLTHIOHYDANTOIN; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR BRN-2; TRANSCRIPTION FACTOR POU; TRANSCRIPTION FACTOR SOX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAS9 GENE; CELL DIFFERENTIATION; CELL PROLIFERATION ASSAY; CHROMATIN IMMUNOPRECIPITATION; CRISPR GENE; FLOW CYTOMETRY; GENE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; TUMOR GROWTH; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CANCER TRANSPLANTATION; DISEASE COURSE; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETIC TRANSCRIPTION; GENETICS; MALE; METABOLISM; PROSTATIC NEOPLASMS; TUMOR CELL LINE; UPREGULATION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKOUT TECHNIQUES; HOMEODOMAIN PROTEINS; HUMANS; MALE; MICE; NEOPLASM TRANSPLANTATION; PHENYLTHIOHYDANTOIN; POU DOMAIN FACTORS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SOXB1 TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 85009354343     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-1263     Document Type: Article

References (62)

1. Ferraldeschi R, Welti J, Luo J, Attard G, de Bono JS. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 2015; 34: 1745–57.
2. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187–97.
3. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 2014; 20: 2846–50.
4. Small EJ, Huang J, Youngren J, Sokolov A, Aggarwal RR, Thomas G, et al. Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). ASCO Annual Meeting 2015; 33 (abstract 5003).
5. Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 2014; 38: 756–67.
6. Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov 2011; 1: 466–8.
7. Alanee S, Moore A, Nutt M, Holland B, Dynda D, El-Zawahry A, et al. Contemporary incidence and mortality rates of neuroendocrine prostate cancer. Anticancer Res 2015; 35: 4145–50.
8. Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res 2014; 20: 890–903.
9. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 2012; 18: 666–77.
10. Chen H, Sun Y, Wu C, Magyar CE, Li X, Cheng L, et al. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr Relat Cancer 2012; 19: 321–31.
11. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1: 487–95.
12. Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, et al. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Rep 2015; 12: 922–36.
13. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012; 227: 286–97.
14. Zhang X, Coleman IM, Brown LG, True LD, Kollath L, Lucas J M, et al. SRRM4 expression and the loss of REST activity may promote the emergence of the neuroendocrine phenotype in Castration-Resistant Prostate Cancer. Clin Cancer Res 2015; 21: 4698–708.
15. Svensson C, Ceder J, Iglesias-Gato D, Chuan YC, Pang ST, Bjartell A, et al. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res 2014; 42: 999–1015.
16. Wee ZN, Li Z, Lee PL, Lee ST, Lim YP, Yu Q. EZH2-mediated inactivation of IFN-gamma-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer. Cell Rep 2014; 8: 204–16.
17. Li Y, Donmez N, Sahinalp C, Xie N, Wang Y, Xue H, et al. SRRM4 drives neuroendocrine transdifferentiation of prostate adenocarcinoma under androgen receptor pathway inhibition. Eur Urol 2016 May 11. pii: S0302-2838(16)30138-5. doi: 10.1016/j.eururo.2016.04.028. [Epub ahead of print].
18. Abrahamsson PA. Neuroendocrine differentiation and hormonerefractory prostate cancer. Prostate Suppl 1996; 6: 3–8.
19. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999; 162: 1800–5.
20. Hu CD, Choo R, Huang J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front Oncol 2015; 5: 90.
21. Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, et al. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate 2013; 73: 306–15.
22. Rapa I, Volante M, Migliore C, Farsetti A, Berruti A, Vittorio Scagliotti G, et al. Human ASH-1 promotes neuroendocrine differentiation in androgen deprivation conditions and interferes with androgen responsiveness in prostate cancer cells. Prostate 2013; 73: 1241–9.
23. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013; 155: 1309–22.
24. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, e t al. Therapeutic targeting of BET bromodomain proteins in castrationresistant prostate cancer. Nature 2014; 510: 278–82.
25. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife 2013; 2: e00499.
26. Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell R H, et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res 2015; 21: 2315–24.
27. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 2013; 3: 1020–9.
28. Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 2013; 3: 1030–43.
29. Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, et al. N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells. Cancer Cell 2016; 29: 536–47.
30. Hubbard GK, Mutton LN, Khalili M, McMullin RP, Hicks JL, Bianchi- Frias D, et al. Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer. Cancer Res 2016; 76: 283–92.
31. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004; 64: 2270–305.
32. Dominguez MH, Ayoub AE, Rakic P. POU-III transcription factors (Brn1, Brn2, and Oct6) influence neurogenesis, molecular identity, and migratory destination of upper-layer cells of the cerebral cortex. Cereb Cortex 2013; 23: 2632–43.
33. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 2016; 22: 298–305.
34. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, et al. Pathobiology of autochthonous prostate cancer in a preclinical transgenic mouse model. Prostate 2003; 55: 219–37.
35. Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 2014; 9: e87705.
36. Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res 2014; 74: 1272–83.
37. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239–43.
38. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11–22.
39. Barton BE, Murphy TF, Shu P, Huang HF, Meyenhofer M, Barton A. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol Cancer Ther 2004; 3: 1183–91.
40. Yu X, Cates JM, Morrissey C, You C, Grabowska MM, Zhang J, et al. SOX2 expression in the developing, adult, as well as, diseased prostate. Prostate Cancer Prostatic Dis 2014; 17: 301–9.
41. Dailey L, Basilico C. Coevolution of HMG domains and homeodomains and the generation of transcriptional regulation by Sox/POU complexes. J Cell Physiol 2001; 186: 315–28.
42. Lodato MA, Ng CW, Wamstad JA, Cheng AW, Thai KK, Fraenkel E, et al. SOX2 co-occupies distal enhancer elements with distinct POU factors in ESCs and NPCs to specify cell state. PLoS Genet 2013; 9: e1003288.
43. Kregel S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, Otto KB, et al. Sox2 is an androgen receptor-repressed gene that promotes castrationresistant prostate cancer. PLoS One 2013; 8: e53701.
44. Iwafuchi-Doi M, Yoshida Y, Onichtchouk D, Leichsenring M, Driever W, Takemoto T, et al. The Pou5f1/Pou3f-dependent but SoxBindependent regulation of conserved enhancer N2 initiates Sox2 expression during epiblast to neural plate stages in vertebrates. Dev Biol 2011; 352: 354–66.
45. Sakaeda M, Sato H, Ishii J, Miyata C, Kamma H, Shishido-Hara Y, et al. Neural lineage-specific homeoprotein BRN2 is directly involved in TTF1 expression in small-cell lung cancer. Lab Invest 2013; 93: 408–21.
46. Ishii J, Sato H, Sakaeda M, Shishido-Hara Y, Hiramatsu C, Kamma H, et al. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer. Pathol Int 2013; 63: 158–68.
47. Endo T, Yazawa T, Shishido-Hara Y, Fujiwara M, Shimoyamada H, Ishii J, et al. Expression of developing neural transcription factors in lung carcinoid tumors. Pathol Int 2014; 64: 365–74.
48. Berlin I, Denat L, Steunou AL, Puig I, Champeval D, Colombo S, et al. Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation. Mol Cell Biol 2012; 32: 1237–47.
49. Boyle GM, Woods SL, Bonazzi VF, Stark MS, Hacker E, Aoude L G, et al. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res 2011; 24: 525–37.
50. Pinner S, Jordan P, Sharrock K, Bazley L, Collinson L, Marais R, et al. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res 2009; 69: 7969–77.
51. Bae KM, Su Z, Frye C, McClellan S, Allan RW, Andrejewski J T, et al. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 2010; 183: 2045–53.
52. Jia X, Li X, Xu Y, Zhang S, Mou W, Liu Y, et al. SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol 2011; 3: 230–8.
53. Lin F, Lin P, Zhao D, Chen Y, Xiao L, Qin W, et al. Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis. Cell Prolif 2012; 45: 207–16.
54. Graham V, Khudyakov J, Ellis P, Pevny L. SOX2 functions to maintain neural progenitor identity. Neuron 2003; 39: 749–65.
55. Catena R, Tiveron C, Ronchi A, Porta S, Ferri A, Tatangelo L, et al. Conserved POU binding DNA sites in the Sox2 upstream enhancer regulate gene expression in embryonic and neural stem cells. J Biol Chem 2004; 279: 41846–57.
56. Ugolkov AV, Eisengart LJ, Luan C, Yang XJ. Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate 2011; 71: 18–25.
57. Sholl LM, Long KB, Hornick JL. Sox2 expression in pulmonary nonsmall cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol 2010; 18: 55–61.
58. Morise M, Hishida T, Takahashi A, Yoshida J, Ohe Y, Nagai K, et al. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung. J Cancer Res Clin Oncol 2015; 141: 2121–30.
59. Laga AC, Lai CY, Zhan Q, Huang SJ, Velazquez EF, Yang Q, et al. Expression of the embryonic stem cell transcription factor SOX2 in human skin: relevance to melanocyte and Merkel cell biology. Am J Pathol 2010; 176: 903–13.
60. Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, et al. A novel antiandrogen, Compound 30, suppresses castrationresistant and MDV3100-resistant prostate cancer growth in vitro and in vivo. Mol Cancer Ther 2013; 12: 567–76.
61. Wyatt AW, Mo F, Wang K, McConeghy B, Brahmbhatt S, Jong L, et al. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol 2014; 15: 426.
62. Goodall J, Wellbrock C, Dexter TJ, Roberts K, Marais R, Goding CR. The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell Biol 2004; 24: 2923–31.